850646-50-3

Upstream product

• 958852-73-8 (S)-2-benzyloxycarbonylamino-4,4-difluoro-5-phenylpentanoic acid 
• 153413-52-6 (S)-2-benzyloxycarbonylamino-3-chlorocarbonyl-propionic acid methyl ester 
• 4668-42-2 (S)-2-benzyloxycarbonylamino-succinic acid 1-methyl ester 
• 850646-48-9 (2S)-2-benzyloxycarbonylamino-4-oxo-5-phenylpentanoic acid methyl ester 

Downstream Products

• 850646-51-4 (S)-2-amino-4,4-difluoro-5-phenyl-pentanoic acid methyl ester 
• 1017934-67-6 (S)-4,4-difluoro-5-phenyl-2-((S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethylamino)pentanoic acid 
• 1017930-77-6 (S)-N-(1-cyanocyclopropyl)-4,4-difluoro-5-phenyl-2-((S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethylamino)pentanamide 
• 1017932-93-2 (S)-methyl 2-amino-4,4-difluoro-5-phenylpentanoate hydrobromide 

Relevant academic research and scientific papers

DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Spirocyclic nitriles as protease inhibitors

The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.

DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS

Novel difluorinated amide derivatives of Formula (II) as inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.